Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jun 17

PMID 27310135

Citations 13

Authors

Yaoyao Lu

Meng Chen

Zhiyin Huang

Chengwei Tang

Affiliations

Soon will be listed here.

Abstract

Background: Antidepressants have been empirically used in the treatment of functional dyspepsia (FD). However, results from recent clinical trials investigating their efficacy are conflicting. The aim of this study is to evaluate the efficacy of antidepressants in the management of FD in adults.

Methods: Databases of MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and BIOSIS Previews were searched for all randomized controlled trials (RCT) investigating efficacy of antidepressants in the management of FD in adult patients. Data of overall symptom unimproved and adverse events were compared between the antidepressants and placebo group.

Results: The search strategy identified 432 citations. Of those, eight RCTs met the inclusion criteria and were included in the meta-analysis. The pooled relative risk (RR) of symptom unimproved with tricyclic antidepressants (TCAs) versus placebo was 0.76 (95% CI: 0.62 to 0.94, P = 0.01; I2 = 0%, P = 0.39). By contrast, selective serotonin reuptake inhibitors (SSRIs) did not show a benefit over placebo (RR = 1.00, 95% CI: 0.86 to 1.17, P = 0.95; I2 = 0%, P = 0.82). Adverse events were significantly more frequent among patients receiving antidepressants than those receiving placebos (RR = 1.64, 95% CI: 1.14 to 2.35, P = 0.007).

Conclusion: TCAs but not SSRIs, are effective in the treatment of FD, but antidepressants were also associated with more adverse events compared with placebo.

Citing Articles

Functional dyspepsia and gastroparesis: are they distinct disorders, a spectrum of diseases or one disease?.

Egboh S, Duncanson K, Potter M, Keely S, Talley N eGastroenterology. 2025; 3(1):e100119.

PMID: 39944931 PMC: 11770444. DOI: 10.1136/egastro-2024-100119.

Clinical Trial: Efficacy of Mosapride Controlled-release and Nortriptyline in Patients With Functional Dyspepsia: A Multicenter, Double-placebo, Double-blinded, Randomized Controlled, Parallel Clinical Study.

Tae C, Cha R, Oh J, Gweon T, Park J, Bang K J Neurogastroenterol Motil. 2024; 30(1):106-115.

PMID: 38173162 PMC: 10774802. DOI: 10.5056/jnm23147.

Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis.

Qi Q, Wang N, Liu H, Li Y BMC Gastroenterol. 2023; 23(1):370.

PMID: 37907846 PMC: 10617220. DOI: 10.1186/s12876-023-03014-9.

Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report.

Syam A, Miftahussurur M, Makmun D, Abdullah M, Rani A, Siregar G Gut Pathog. 2023; 15(1):25.

PMID: 37217981 PMC: 10202071. DOI: 10.1186/s13099-023-00551-2.

Pharmacological Treatment of Functional Dyspepsia: An Old Story Revisited or a New Story to Be Told? A Clinical Review.

Chaves J, Pita I, Libanio D, Pimentel-Nunes P GE Port J Gastroenterol. 2023; 30(2):86-97.

PMID: 37008521 PMC: 10050843. DOI: 10.1159/000526674.

References

Hashash J, Abdul-Baki H, Azar C, Elhajj I, El Zahabi L, Chaar H . Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. Aliment Pharmacol Ther. 2008; 27(11):1148-55. DOI: 10.1111/j.1365-2036.2008.03677.x. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

van Kerkhoven L, Laheij R, Aparicio N, de Boer W, Van den Hazel S, Tan A . Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2008; 6(7):746-52. DOI: 10.1016/j.cgh.2008.02.051. View

Koloski N, Talley N, Boyce P . The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol. 2000; 95(1):67-71. DOI: 10.1111/j.1572-0241.2000.01735.x. View

Koloski N, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley N . The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012; 61(9):1284-90. DOI: 10.1136/gutjnl-2011-300474. View

Wang W, Huang J, Zheng G, Xia H, Wong W, Liu X . Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2006; 5(2):178-85. DOI: 10.1016/j.cgh.2006.09.012. View

Cheong P, Ford A, Cheung C, Ching J, Chan Y, Sung J . Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2018; 3(12):837-844. DOI: 10.1016/S2468-1253(18)30303-0. View

Wang W, Sun Y, Wang Y, Wang Y, Wang W, Li Y . Treatment of functional chest pain with antidepressants: a meta-analysis. Pain Physician. 2012; 15(2):E131-42. View

Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M . Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol. 2007; 22(3):304-10. DOI: 10.1111/j.1440-1746.2006.04493.x. View

10.

Talley N, Locke G, Lahr B, Zinsmeister A, Cohard-Radice M, DElia T . Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther. 2006; 23(7):923-36. DOI: 10.1111/j.1365-2036.2006.02845.x. View

11.

Ford A, Talley N, Schoenfeld P, Quigley E, Moayyedi P . Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2008; 58(3):367-78. DOI: 10.1136/gut.2008.163162. View

12.

Tack J, Talley N, Camilleri M, Holtmann G, Hu P, Malagelada J . Functional gastroduodenal disorders. Gastroenterology. 2006; 130(5):1466-79. DOI: 10.1053/j.gastro.2005.11.059. View

13.

Aro P, Talley N, Ronkainen J, Storskrubb T, Vieth M, Johansson S . Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology. 2009; 137(1):94-100. DOI: 10.1053/j.gastro.2009.03.039. View

14.

Tack J, Broekaert D, Coulie B, Fischler B, Janssens J . Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther. 2003; 17(4):603-8. DOI: 10.1046/j.1365-2036.2003.01469.x. View

15.

Otaka M, Jin M, Odashima M, Matsuhashi T, Wada I, Horikawa Y . New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther. 2005; 21 Suppl 2:42-6. DOI: 10.1111/j.1365-2036.2005.02473.x. View

16.

Lu C, Lang H, Chang F, Chen C, Luo J, Wang S . Prevalence and health/social impacts of functional dyspepsia in Taiwan: a study based on the Rome criteria questionnaire survey assisted by endoscopic exclusion among a physical check-up population. Scand J Gastroenterol. 2005; 40(4):402-11. DOI: 10.1080/00365520510012190. View

17.

Kaosombatwattana U, Pongprasobchai S, Limsrivilai J, Maneerattanaporn M, Leelakusolvong S, Tanwandee T . Efficacy and safety of nortriptyline in functional dyspepsia in Asians: A randomized double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2017; 33(2):411-417. DOI: 10.1111/jgh.13914. View

18.

Yamawaki H, Futagami S, Shimpuku M, Sato H, Wakabayashi T, Maruki Y . Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastroenterol Motil. 2014; 20(1):104-12. PMC: 3895596. DOI: 10.5056/jnm.2014.20.1.104. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

20.

Tanum L, Malt U . A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol. 1996; 31(4):318-25. DOI: 10.3109/00365529609006404. View